Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Rating) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totalling 209,800 shares, a decrease of 17.4% from the June 30th total of 254,100 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 53,700 shares, the short-interest ratio is currently 3.9 days.

Institutional Trading of Vivos Therapeutics

A number of large investors have recently bought and sold shares of VVOS. Russell Investments Group Ltd. boosted its stake in Vivos Therapeutics by 554.0% during the 4th quarter. Russell Investments Group Ltd. now owns 305,096 shares of the company’s stock worth $684,000 after purchasing an additional 258,445 shares during the period. National Asset Management Inc. boosted its stake in Vivos Therapeutics by 55.5% during the 4th quarter. National Asset Management Inc. now owns 79,270 shares of the company’s stock worth $179,000 after purchasing an additional 28,283 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in Vivos Therapeutics by 60.0% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock worth $43,000 after purchasing an additional 7,200 shares during the period. Boston Partners boosted its stake in Vivos Therapeutics by 131.5% during the 4th quarter. Boston Partners now owns 108,015 shares of the company’s stock worth $243,000 after purchasing an additional 61,364 shares during the period. Finally, Griffin Asset Management Inc. boosted its stake in Vivos Therapeutics by 63.3% during the 1st quarter. Griffin Asset Management Inc. now owns 70,200 shares of the company’s stock worth $188,000 after purchasing an additional 27,200 shares during the period. Institutional investors and hedge funds own 9.81% of the company’s stock.

Vivos Therapeutics Trading Down 3.5 %

Shares of Vivos Therapeutics stock opened at $1.11 on Tuesday. The company has a fifty day simple moving average of $1.46 and a 200-day simple moving average of $2.02. Vivos Therapeutics has a 12-month low of $1.09 and a 12-month high of $7.09. The stock has a market cap of $25.54 million, a price-to-earnings ratio of -1.06 and a beta of 1.06.

Vivos Therapeutics (NASDAQ:VVOSGet Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The company had revenue of $3.46 million during the quarter, compared to analyst estimates of $4.50 million. On average, analysts forecast that Vivos Therapeutics will post -1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Craig Hallum lowered their target price on shares of Vivos Therapeutics to $5.00 and set a “na” rating for the company in a report on Tuesday, May 17th.

About Vivos Therapeutics

(Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Featured Stories

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.